In breast cancer (BC), HBXIP can upregulate METTL3 by suppressing miRNA let-7 g, and METTL3 promotes HBXIP expression through increased m6A modification, leading to an accelerated proliferation of BC cells [121]. Here, METTL3 is linked to breast carcinoma.